Study #2022-0687
Phase I/II study of TROP2 CAR engineered IL15-transduced cord blood-derived NK cells delivered intraperitoneally for the management of platinum resistant ovarian cancer, mesonephric-like adenocarcinoma, and pancreatic cancer
MD Anderson Study Status
Enrolling
Treatment Agent
TROP2-CAR-NK, Cyclophosphamide, Fludarabine
Description
To find the recommended dose of TROP2- CAR-NK given intraperitoneally (directly into the abdominal cavity) to patients with highgrade serous ovarian cancer that has not responded to previous treatment or is resistant to treatment.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Pancreatic Cancer, Ovarian Cancer, Adenocarcinoma
Study phase:
Physician name:
Amir Jazaeri
Department:
Gynecologic Oncology & Reproductive Medicine
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.